NASDAQ$CVRX

CVRx Inc · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

CVRx reported a significant revenue increase driven by U.S. heart failure business and expansion of sales territories.

CVRx reported a 241% increase in revenue for the third quarter of 2021, reaching $3.4 million, driven primarily by growth in the U.S. heart failure business. The company's gross profit also saw a substantial increase, while operating expenses rose due to increased headcount and marketing activities. The company continues to expect revenue between $3.9 million and $4.5 million for the fourth quarter of 2021.

  • Revenue increased by 241% to $3.4 million compared to the same quarter last year.
  • U.S. revenue grew by 769% to $2.6 million, driven by the heart failure business.
  • Gross profit increased by 221% to $2.5 million.
  • The company had 38 active implanting centers as of September 30, 2021, compared to 31 as of June 30, 2021.

Headline financials

Total Revenue

$3.4M

Previous: $997K+240.5%
EPS (adj)

-$0.30

Previous: -$8.96+96.6%
Active Implanting Centers in U.S.

38

No prior period
U.S. Revenue Units

84

Previous: 4+2000.0%
Capital Expenditures

-$645K

No prior period
Free Cash Flow

-$6.78M

No prior period
Net Income

-$6.13M

Previous: -$3.23M-90.1%
Operating Income

-$7.29M

Previous: -$3.04M-139.7%
Gross Profit

$2.52M

Previous: $785K+220.9%
Cash & Equivalents

$171M

No prior period
Total Assets

$182M

No prior period
Stock-Based Comp

$474K

No prior period

Revenue & EPS history

CVRx · Revenue · Quarterly

$3.4M

Q3 2021+240.5%vs Q3 2020
Beat estimate in 9 of 11 quarters(82%)
ActualEstimate

Forward guidance

The company expects to report total revenue between $3.9 million and $4.5 million for the fourth quarter of 2021.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

-0.9%

Avg return

Earnings day

-0.4%

Avg return

5 days after

-1.6%

Avg return

30 days after

48%

10 / 21 earnings

Positive

+36.7%

Q3 2024

Best reaction

-39.0%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-6.7%-13.3%-29.2%
Q4 2025-13.0%-14.8%+32.3%
Q3 2025+0.8%-3.4%-8.5%
Q1 2025-39.0%-32.0%-15.7%
Q4 2024-7.2%-8.4%-28.8%
Q3 2024+36.7%+30.2%+48.8%
Q2 2024-17.5%-14.4%+3.3%
Q1 2024-33.8%-39.7%-55.0%
Q4 2023-1.4%-6.1%-19.6%
Q3 2023-1.2%+0.5%+50.4%
Q2 2023+6.2%+5.7%+2.3%
Q1 2023+24.0%+34.2%+41.1%
Q4 2022+3.1%+5.9%-24.2%
Q3 2022+2.7%+21.4%+43.1%
Q2 2022+22.1%+24.6%+4.6%
Q1 2021-3.4%-12.0%-6.3%
Q1 2022+12.6%+28.5%+14.0%
Q4 2021+0.9%+0.0%-21.2%
Q3 2021+4.8%+4.1%-36.5%
Q2 2020-4.7%-13.0%-13.0%
Q2 2021-5.6%-7.5%-15.8%
Q4 2020
Q3 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro